Applied DNA Sciences FY2022 revenue up 101% to $18.2M; operating loss widens to $14.0M

BNB PLUS CORP.

Total revenue $18.2M, +101% YoY; COVID-19 testing revenue $15.5M (85% of total).
Q4 revenue $3.6M (+17% Q/Q, +20% YoY); gross profit margin fell to 12% from 33%.
Operating loss $14.0M vs $13.3M; adjusted EBITDA -$9.9M.
Cash and equivalents $15.2M; secured $12M public offering and $3.7M warrant exercise in Q4.
Company plans cGMP capacity for linearDNA platform by end of CY2023; focuses on PGx testing and UFLP Act.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BNB PLUS CORP. reported the fiscal year ended September 30, 2022 results: revenue $18.2 million.

Period: the fiscal year ended September 30, 2022
Revenue: $18.2 million
Result: reported results

Exact text from the filing

Total revenues increased 101% to $18.2 million, which included $15.5 million in clinical laboratory service revenues (COVID-19 test revenue).

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BNB PLUS CORP. reported the fourth quarter ended September 30, 2022 results: revenue $3.6 million.

Period: the fourth quarter ended September 30, 2022
Revenue: $3.6 million
Result: reported results

Exact text from the filing

Total revenues increased 17% to $3.6 million, which included $2.9 million in clinical laboratory service revenues (COVID-19 testing revenue).

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BNB PLUS CORP. filing history →

Source: SEC EDGAR

accession 0001104659-22-126973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.